Full-Time

Clinical Research Associate

Confirmed live in the last 24 hours

Orca Bio

Orca Bio

51-200 employees

Develops and commercializes cell therapies

No salary listed

Mid, Senior

Remote in USA

Candidates can be based anywhere in the U.S., although west coast is preferred.

Category
Public Health
Biology & Biotech
Required Skills
Google Cloud Platform
Requirements
  • BA/BS or equivalent with a minimum of 3+ years of relevant clinical trial management experience
  • Strong working knowledge of FDA and ICH/GCP regulations and guidelines and thorough knowledge of clinical monitoring procedures
  • Experience with Trial Master File management according to the DIA reference model
  • Experience operating within various site EMR/EHR systems
  • Experience using eTMF, EDC (IBM Zelta experience ideal), CTMS, and other vendors systems/portals
Responsibilities
  • Conduct interim monitoring visits (IMVs) and ISF review
  • Review electronic medical records (EMR)/patient data
  • Source documentation verification (SDV) against case report form data, including informing the site staff of any entry errors, ensuring good documentation practices are being adhered to and communicating protocol deviations appropriately per SOPs, GCP and applicable regulatory requirements
  • Verification and review of adverse events, serious adverse events, concomitant medications and corresponding illnesses to confirm accurate data reporting in accordance with the protocol
  • Provide support to site staff including research coordinators and physicians
  • Assist in the development of trial materials as needed (e.g., case report forms, monitoring guidelines, site tools and training guides)
  • Contribute to the development of Clinical Operations SOPs, best practices, work instructions, tools and templates
Desired Qualifications
  • Therapeutic experience in oncology/hematology and cell and gene therapy preferred
  • Prior CRA experience working directly for sponsor, ideally a start-up/or small company, in a co-monitoring capacity

Orca Bio operates in the biotechnology sector, specifically focusing on cell therapies that utilize the body's own cells to treat diseases. The company aims to enhance these therapies to make them safer and more effective, ultimately improving patient outcomes. Orca Bio's products are designed for healthcare providers who administer these therapies to patients as part of their treatment plans. Unlike many competitors, Orca Bio emphasizes a strong team culture and values communication with stakeholders, keeping them informed about the company's progress and developments. The goal of Orca Bio is to advance cell therapies, addressing healthcare needs for conditions that currently lack effective treatments.

Company Size

51-200

Company Stage

Series D

Total Funding

$192M

Headquarters

Menlo Park, California

Founded

2016

Simplify Jobs

Simplify's Take

What believers are saying

  • Orca-T shows promising relapse-free survival rates in hematologic malignancies.
  • FDA fast-tracking could accelerate Orca Bio's market entry and patient access.
  • Positive clinical data presented at major conferences enhances Orca Bio's credibility.

What critics are saying

  • Increased competition from companies like BlueRock Therapeutics may impact market share.
  • Setbacks in clinical trials could harm Orca Bio's reputation and financial stability.
  • High scrutiny from conference presentations could pressure Orca Bio to deliver consistent results.

What makes Orca Bio unique

  • Orca Bio focuses on high-precision cell therapies for cancer and autoimmune diseases.
  • The company uses single-cell precision to create uniquely-defined cell therapy products.
  • Orca Bio's therapies aim to replace diseased blood and immune systems with healthy ones.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Unlimited Paid Time Off

401(k) Retirement Plan

Parental Leave

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Business Wire
Jan 6th, 2025
Orca Bio to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Orca Bio to present at the 43rd Annual J.P. Morgan Healthcare Conference.

Labiotech
May 30th, 2024
Stem Cell Therapy’S Avant-Garde: Eight Companies Leading The Way

The field of stem cell therapy has gained traction over recent years, with companies transitioning from experimental stages to delivering practical treatments. Stem cells, with their unique ability to differentiate into various cell types, hold great potential in regenerative medicine.One of the most notable advancements in stem cell therapy is its application in treating neurodegenerative diseases such as Parkinson’s disease. Companies like BlueRock Therapeutics have pioneered the development of dopamine-producing neural cells derived from stem cells potentially altering the disease course​. Stem cell therapy has also shown potential in repairing damaged heart tissue or in cancer treatment research.In this article, we delve into stem-cell-oriented biotech companies to know about.Table of contentsAspen NeuroscienceAspen Neuroscience was founded in 2018, and is headquartered in San Diego. It is a clinical-stage company focused on developing personalized stem cell therapies to treat neurodegenerative diseases, with an initial emphasis on Parkinson’s disease.Aspen Neuroscience’s lead candidate, ANPD001, is an autologous induced pluripotent stem cell (iPSC)-derived neuron replacement therapy aimed at treating Parkinson’s disease. This therapy is designed to replace the lost dopamine neurons that are characteristic of the disease, potentially reversing its effects.Aspen’s technology lies in the use of autologous iPSCs

Business Wire
Apr 11th, 2024
Orca Bio To Present Positive Clinical Data On Orca-T At The 50Th Annual Meeting Of The Ebmt

MENLO PARK, Calif.--(BUSINESS WIRE)--Orca Bio, a late-stage biotechnology company developing high-precision cell therapies for the treatment of cancer, autoimmune diseases and genetic blood disorders, today announced new data will be presented during the 50th Annual Meeting of the EBMT in Glasgow, United Kingdom. Specifically, results from a single-center open-label Phase 1 clinical trial of an expanded group of older patients (n=20) treated with Orca Bio’s lead investigational high-precision cell therapy, Orca-T, and a reduced intensity conditioning (RIC) regimen will be presented. Preliminary data with Orca-T and RIC in patients with hematologic malignancies showed encouraging rates of relapse-free survival (77%). With a median follow-up of 9.65 months, no patients have experienced relapse to date (0%), demonstrating the curative potential for Orca-T in this historically challenging to treat patient group. An earlier dataset evaluating Orca-T and RIC in this population was presented at the 2023 American Society of Hematology (ASH) Annual Meeting. A second presentation will highlight findings from a non-randomized retrospective analysis comparing Orca-T plus single-agent tacrolimus with a standard of care allogeneic stem cell transplant (alloHSCT) plus post-transplant cyclophosphamide (PTCy)-based graft versus host disease (GvHD) prophylaxis in patients with hematologic malignancies receiving myeloablative conditioning (MAC)

Business Wire
Feb 23rd, 2024
Orca Bio Presents Promising Data On Orca-T In Two Oral Presentations At The 2024 Tandem Meetings Of Astct® And Cibmtr®

MENLO PARK, Calif.--(BUSINESS WIRE)--Orca Bio, a late-stage biotechnology company developing high-precision cell therapies for the treatment of cancer, autoimmune diseases and genetic blood disorders, today announced positive data on its lead investigational high-precision cell therapy, Orca-T, presented at the 2024 Tandem Meetings, Transplantation Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood and Marrow Transplant Research (CIBMTR). In the first of two oral presentations, findings from a retrospective analysis compared historical outcomes between Orca-T and a standard of care allogeneic stem cell transplant (alloHSCT) plus post-transplant cyclophosphamide (PTCy)-based graft versus host disease (GvHD) prophylaxis in patients with hematologic malignancies receiving myeloablative conditioning (MAC). Within the non-randomized cohorts of varying conditioning regimens and disease types, Orca-T demonstrated favorable results across clinical outcomes including relapse-free survival (RFS), non-relapse mortality (NRM) and overall survival (OS). “When treating hematological malignancies, physicians are often faced with compromising between the risk of relapse and the risk of serious toxicities, all of which can impact overall patient survival,” said Alexandra Gomez-Arteaga, MD, Assistant Professor of Medicine at Weill Cornell Medicine, hematologist oncologist in the Bone Marrow Transplant and Cellular Therapy Program at NewYork-Presbyterian/Weill Cornell Medical Center, and presenting author. “While advances in prophylaxis agents have demonstrated improvements in reducing the rate of graft versus host disease, the findings of this retrospective analysis suggest Orca-T may also provide benefits across key survival metrics, further highlighting the importance of identifying novel approaches that may offer enhancements across all patient outcomes.”

BioSpace
Jan 3rd, 2024
Orca Bio To Present At The 42Nd Annual J.P. Morgan Healthcare Conference

MENLO PARK, Calif.--(BUSINESS WIRE)-- Orca Bio, a late-stage biotechnology company developing high-precision cell therapies for the treatment of cancer, autoimmune diseases and genetic blood disorders, today announced that Ivan Dimov, Ph.D., Orca Bio’s co-founder and chief executive officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference.The company presentation will take place on Monday, January 8, 2024, at 2:00PM PST at the Westin St. Francis in the Golden Gate Room on the 32nd floor.About Orca BioOrca Bio is a late-stage biotechnology company developing high-precision cell therapies for the treatment of cancer, autoimmune diseases and genetic blood disorders. Our investigational products are designed to safely replace a patient’s diseased blood and immune system with a healthy one, delivering significantly better outcomes with dramatically fewer risks than the standard of care. Our manufacturing platform uses single-cell precision to create proprietary, uniquely-defined products that have the potential to transform allogeneic cell therapy. At Orca Bio, our mission is to make curative cell therapies both more effective and safer, and in doing so, push past the field’s current boundaries and redefine its future